Ensign Peak Advisors
JAZZ icon

Ensign Peak Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Ensign Peak Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.26M Buy
17,679
+3,613
+26% +$792K 0.01% 598
2026
Q1 		$2.66M Sell
14,066
-13,530
-49% -$2.36M 0.01% 653
2025
Q4 		$4.69M Sell
27,596
-8,539
-24% -$1.31M 0.01% 533
2025
Q3 		$4.76M Buy
36,135
+7,700
+27% +$924K 0.01% 601
2025
Q2 		$3.02M Buy
28,435
+4,316
+18% +$469K 0.01% 773
2025
Q1 		$2.99M Sell
24,119
-245
-1% -$32K 0.01% 769
2024
Q4 		$3M Sell
24,364
-1,883
-7% -$222K 0.01% 794
2024
Q3 		$2.92M Sell
26,247
-1,837
-7% -$201K 0.01% 792
2024
Q2 		$3M Sell
28,084
-1,245
-4% -$137K 0.01% 772
2024
Q1 		$3.53M Sell
29,329
-5,615
-16% -$688K 0.01% 743
2023
Q4 		$4.3M Buy
34,944
+3,615
+12% +$451K 0.01% 662
2023
Q3 		$4.06M Buy
31,329
+7,429
+31% +$990K 0.01% 628
2023
Q2 		$2.96M Sell
23,900
-3,740
-14% -$503K 0.01% 743
2023
Q1 		$4.04M Buy
27,640
+1,535
+6% +$227K 0.01% 628
2022
Q4 		$4.16M Sell
26,105
-430
-2% -$63K 0.01% 603
2022
Q3 		$3.54M Sell
26,535
-850
-3% -$129K 0.01% 618
2022
Q2 		$4.27M Buy
27,385
+3,975
+17% +$612K 0.01% 580
2022
Q1 		$3.64M Sell
23,410
-5,120
-18% -$743K 0.01% 676
2021
Q4 		$3.64M Sell
28,530
-76,190
-73% -$10M 0.01% 762
2021
Q3 		$13.6M Sell
104,720
-28,375
-21% -$4.29M 0.03% 374
2021
Q2 		$23.6M Sell
133,095
-3,145
-2% -$545K 0.05% 292
2021
Q1 		$22.4M Sell
136,240
-46,170
-25% -$7.6M 0.05% 293
2020
Q4 		$30.1M Sell
182,410
-85,340
-32% -$12.7M 0.07% 245
2020
Q3 		$38.2M Buy
267,750
+7,130
+3% +$884K 0.1% 175
2020
Q2 		$28.8M Sell
260,620
-49,430
-16% -$5.47M 0.08% 219
2020
Q1 		$30.9M Buy
310,050
+710
+0.2% +$91.8K 0.1% 146
2019
Q4 		$46.2M Buy
+309,340
New +$42.1M 0.12% 138

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Ensign Peak Advisors's JAZZ Position: Q2 2026 in Review

Ensign Peak Advisors increased its Jazz Pharmaceuticals (JAZZ) stake by 26% in Q2 2026, buying an estimated $792K and bringing the position to 17,679 shares worth $4.26M. The position accounts for 0.01% of the portfolio, ranked #598.

Ensign Peak Advisors first reported a position in JAZZ in Q4 2019 and has held it in 27 quarters since. The position peaked at $46.2M in Q4 2019. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Ensign Peak Advisors held 17,679 shares of Jazz Pharmaceuticals worth $4.26M as of Q2 2026.
  • Ensign Peak Advisors bought 3,613 Jazz Pharmaceuticals shares in Q2 2026, an estimated $792K.
  • Jazz Pharmaceuticals made up 0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #598 holding.
  • Ensign Peak Advisors first reported a position in Jazz Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Ensign Peak Advisors's Jazz Pharmaceuticals position peaked at $46.2M in Q4 2019.
  • 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.